Vasundhara Rasayans Ltd

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very expensive rating to a fair valuation grade. This change, coupled with its current price-to-earnings (P/E) ratio of 13.14 and price-to-book value (P/BV) of 1.40, suggests a more attractive entry point for investors compared to its historical and peer averages.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 June 2026, providing investors with the latest insights into its performance and outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a robust intraday price surge of 19.98% to ₹148.90 on 1 June 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment compared to its historical averages and peer benchmarks.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Vasundhara Rasayans Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging price performance relative to the Sensex. This repositioning is underpinned by a significant contraction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggesting a potential entry point for value-focused investors within the Pharmaceuticals & Biotechnology sector.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in investor sentiment. Despite a modest day gain of 0.27%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now align more closely with sector averages, signalling a recalibration of its price attractiveness amid challenging market returns.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 December 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 22 April 2026, providing investors with the latest insights into its performance and prospects.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. Despite a robust day gain of 9.33%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market enthusiasm compared to its historical averages and peer benchmarks. This article analyses the implications of these valuation changes in the context of the company’s financial metrics, sector dynamics, and relative performance against peers and the broader market.

Vasundhara Rasayans Ltd’s share price declined to a fresh 52-week low of Rs.100.1 on 30 March 2026, marking a significant milestone in the stock’s downward trajectory amid broader market weakness and company-specific performance concerns.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 March 2026, providing investors with the latest insights into the stock’s performance and outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid a challenging price performance and a competitive peer landscape. Investors are advised to carefully analyse the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios in relation to historical averages and sector benchmarks to assess its price attractiveness.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.101.15 today, marking a significant decline amid a volatile trading session. The stock’s performance continues to lag behind broader market indices and sector peers, reflecting ongoing pressures on its financial metrics and market positioning.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a challenging market environment and significant share price declines, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value investors seeking opportunities in the sector.